Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab
{{output}}
Nemolizumab demonstrates efficacy against pruritus and eczema by inhibiting IL-31 signaling in patients with atopic dermatitis. However, its effect on the systemic immune response at the molecular level remains unknown. In this study, we aimed to elucidate it ... ...
